# AccuraGen

Source: https://onco.cc/companies/accuragen/  
OnCo record `accuragen` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A Californian company behind AccuScan, a whole-genome blood test for leftover cancer that corrects sequencing errors read by read.

## Summary

AccuraGen Inc of San Jose, California, developed AccuScan with Shanghai YunSheng Medical Laboratory, according to the affiliations of the 2024 EMBO Molecular Medicine paper describing it. Its website could not be reached when this record was written.

## Fields

- Kind: Company
- Last checked: 2026-11-04
- HQ: San Jose, CA
- Type: diagnostics

## Sources

- Li et al., AccuScan (EMBO Molecular Medicine 2024): https://doi.org/10.1038/s44321-024-00115-0

## Connected records

- fronts: [Diagnostics & Biomarkers](https://onco.cc/fronts/diagnostics/)
- technologies: [Liquid biopsy (ctDNA)](https://onco.cc/technologies/liquid-biopsy/), [MRD / molecular residual disease testing](https://onco.cc/technologies/mrd-testing/)
- key papers: [Ultra-sensitive molecular residual disease detection through whole genome sequencing with single-read error correction](https://onco.cc/key-papers/paper-li-accuscan-embo-mol-med-2024/)
- drugs: [AccuScan](https://onco.cc/drugs/accuscan-mrd/)

---
JSON: https://onco.cc/api/v1/entities/accuragen.json